Pure Global

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease - Trial NCT05573464

Access comprehensive clinical trial information for NCT05573464 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 542 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05573464
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT05573464
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, 12-Week (With an Extension to 52 Weeks in a Subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared to BGF Delivered by MDI HFA in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Focus

BGF MDI HFO 320/14.4/9.6 ฮผg

Interventional

drug

Sponsor & Location

AstraZeneca

Phoenix,Newport Beach,Miami,Sarasota,Tampa,Valparaiso,Crowley,North Dartmouth,Saint Louis,Charlotte,Wilmington,Dublin,Grants Pass,Portland,Anderson,Columbia,Gaffney,Longview,McKinney,Richmond,Buenos A, Argentina,Bulgaria,Canada,Germany,Mexico,Poland,Turkey,United Kingdom,United States of America

Timeline & Enrollment

Phase 3

Sep 27, 2022

Jun 21, 2024

542 participants

Primary Outcome

Number (and percentage) of participants with adverse Events - AEs (including SAEs, DAEs, AEOSIs, non-serious AEs),Number (and percentage) of participants with potentially clinically significant changes in Digital 12-lead Holter electrocardiogram (ECG),Number (and percentage) of participants with potentially clinically significant changes in 12-lead ECG,Number (and percentage) of participants with potentially clinically significant changes in laboratory values (hematology, clinical chemistry and urinalysis),Number (and percentage) of participants with potentially clinically significant changes in Blood Pressure,Number (and percentage) of participants with potentially clinically significant changes in pulse rate,Number (and percentage) of participants with potentially clinically significant changes in respiratory rate,Number (and percentage) of participants with potentially clinically significant changes in body temperature

Summary

This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing
 the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with
 moderate to very severe COPD.

ICD-10 Classifications

Other chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease, unspecified
Other specified chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
Chronic obstructive pulmonary disease with acute lower respiratory infection

Data Source

ClinicalTrials.gov

NCT05573464

Non-Device Trial